Executive record

Wayne Pisano

Director at Altimmune, Inc.

Follow
More
Challenge a Claim

Alpha ID: alpha:person:wayne-pisanoVersion: public-0As of: 2026-09-28

Not yet claimed10 published Claims4 sources
  • Director

Key Claims

Biography

Director since May 2013 and served as Interim CEO from June 2024 to June 2025. More than 30 years of pharmaceutical industry executive experience, including president and CEO of VaxInnate and Sanofi Pasteur, and 11 years with Novartis.

Alpha editorial summary written from the cited sources below. It does not change any Claim on this record.

Board service

Boards

Claims

Executive career

  1. 2026 to end not publishedExecutive title: Director and Chair · Organization not publishedONCY 10-K executive officers

Claims

Conflicts and accountability

Alpha has not published independence, related-party, proceedings or disciplinary Claims for this record. This is not a finding that none exist.

Only disclosed facts and public registers appear here. Executive records carry no credit, personal litigation, background screening or underwriting views. None observed is not a clearance.

Evidence, history and coverage

Additional published Claims

Published evidence records

4 evidence records, matching Agent View. Records may refer to different locations or observations in the same document. This count is not a count of independent corroborating sources.

  1. ONCY 10-K executive officers

    sec filing · Source published: Mar 30, 2026 · Retrieved: May 16, 2026

    Supports 6 claims
    • AI and ML experience: AI and ML experience: not identified in the cited filing · Claim reviewed: May 16, 2026
    • Cybersecurity experience: Cybersecurity experience: not identified in the cited filing · Claim reviewed: May 16, 2026
    • Executive company: Executive at ONCOLYTICS BIOTECH INC · Claim reviewed: May 16, 2026
    • Executive title: Executive title: Director and Chair · Claim reviewed: May 16, 2026
    • Other Company Role: Wayne Pisano is also linked to Oncolytics Biotech Inc. as Interim Chief Executive Officer. · Claim reviewed: May 16, 2026
    • Technology background: Technology background: not identified in the cited filing · Claim reviewed: May 16, 2026

  2. ALT DEF 14A director slate

    sec filing · Source published: Mar 17, 2026 · Retrieved: May 15, 2026

    Supports 5 claims
    • AI and ML experience: AI and ML experience: not identified in the cited filing · Claim reviewed: May 16, 2026
    • Board role: Board role: Lead Independent Director · Claim reviewed: May 15, 2026
    • Committee assignments: Committee assignments: Nominating/Governance · Claim reviewed: May 15, 2026
    • Cybersecurity experience: Cybersecurity experience: not identified in the cited filing · Claim reviewed: May 16, 2026
    • Technology background: Technology background: not identified in the cited filing · Claim reviewed: May 16, 2026

  3. Open source

    sec proxy · Source published: Mar 17, 2026 · Retrieved: Apr 24, 2026

    Supports 1 claim
    • Professional Role: Director at Altimmune, Inc. · Claim reviewed: May 16, 2026

  4. Open source

    public source · Source published: Date unavailable · Retrieved: Date unavailable

    Supports 1 claim
    • Board membership: Serves on the board of Altimmune, Inc. · Claim reviewed: May 16, 2026